Gastrointestinal Disorders Market Intelligence to 2012

Gastrointestinal (GI) disorders are set to affect over 250 million people in the seven largest pharma markets, by 2012. As generations of people become more obese and consume increasingly poor diets then so too will the number of people suffering from these disorders rise.

At present, the pharmaceutical prescription market to treat GI disorders market is valued at just over $20 billion, reflecting that it is one of the largest and most important therapeutic areas in the pharmaceutical industry. Visiongain has just produced a business intelligence report, Gastrointestinal Disorders 2007-2012, which addresses the state of this market, and assesses how it will develop in the future. Are you involved in this market area? Will the future of this market affect your business?

AstraZeneca’s Nexium is currently the most successful GI drug available in the market, based on sales revenues totalling more than $6 billion. What is the future for Nexium? How will its impact shape the GI market? Will other GI drugs reach blockbuster status? If so, which ones? Find out in this vital report.

Another example of change in the GI market is the withdrawal of Novartis’s from the US market, due to safety and efficacy issues. What effects will this have on the other GI drugs? How will this affect the overall GI market? What does the future hold for Novartis and Zelnorm? These are all crucial questions that need answers, which can be found by buying this visiongain report.

Visiongain’s World Gastrointestinal Disorders report includes three major classes of product which visiongain believes will extensively occupy the GI market. These are:

Proton Pump Inhibitors (PPIs)

Histamine H2 Receptor Antagonists

Other Leading GI agents

Which new drugs will be marketed? Which drugs will have the most impact on the market? Most importantly, what are the future prospects of the GI market?

The following crucial aspects of the GI market are discussed:

The current world GI market

SWOT Analysis of the GI market

Revenue Forecasts for all the drugs analysed 2007-2012

Market Activity

Geographical breakdown of GI market

Potential treatment population forecasted to 2012 for major leading global markets

Discussion on comparative pricing of the major GI drugs

Analysing the major generic/substitute products

Detailed information on pipeline products

Discussion on possible future strategies in GI market

Why You Must Buy This Report:

This 180+ paged report features 47 figures which includes graphs and charts, 28 tables, insight, and include the latest developments in the gastrointestinal market with up-to-date analysis.

This report will give you the understanding you require to gain that competitive edge in the GI market. This large revenue producing therapeutic area is in the top ten of the largest earning revenues in the pharma industry. Therefore, it is vital that the latest gastrointestinal report is brought without fail.

The revenue forecasts generated in this report are highly accurate and are determined by the market and its future prospects in terms of patent protection, generic competition, life-cycle management, licensing agreements and market activity. The forecast runs up to 2012. Therefore it gives your company sound understanding of how GI drug will behave up until that time.

Key questions that this report answers:

What are the most influential GI disorders and their impacts?

Which drugs are dominating their classes in the GI market?

What is the revenue potential in 2012 for these drugs?

What market activity is occurring? (What are pharma companies doing?)

What is the potential population treatment in the major global markets up to 2012?

Which is the status of the GI pipeline?

Unique benefits to you when you order this report:

- Immediate access through our exclusive Reading Room

- You can access your report whichever country you are in without using hard drive space

- Primary research throughout. You will not find this information anywhere else

- Report stored in your reading room for ever

- Full searchable report when you buy the company or corporate editions

- Copies can be printed off for offline reading

- Packed with charts, analysis, figures, graphs and tables

Publication Date: 25/05/07

Pages: 185

PDF Format
Table of Contents

Price
Single User Licence $2998.00
Department Licence 5 Users $5,998.00
Company-wide Intranet Licence $9,998.00